A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)

NCT02942017 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Postpartum Depression

Interventions

DRUG: Placebo
DRUG: SAGE-547 90 μg/kg/h

Sponsor

Supernus Pharmaceuticals, Inc.